Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | USP1 | O94782 | 1/20 | 0.39 |
| ▸ | USP8 | P40818 | 1/20 | 0.39 |
| ▸ | OTUB1 | Q96FW1 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14391801 | 0.76 | AKT1 (0.48) | PDE10ASOS1 | |
| SCHEMBL30979869 | 0.76 | AKT1 (0.48) | PDE10ASOS1 | |
| SCHEMBL24322991 | 0.74 | CLK2 (0.44) | CHEK2 | |
| SCHEMBL189416 | 0.73 | HRH3 (0.54) | CHEK2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL24596865 | 0.73 | HRH3 (0.54) | CHEK2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL24596869 | 0.73 | HRH3 (0.54) | CHEK2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL30979897 | 0.72 | EGFR (0.57) | — | |
| SCHEMBL25335531 | 0.71 | CYP3A4 (0.46) | CHEK2 | |
| SCHEMBL30514943 | 0.71 | CYP3A4 (0.46) | CHEK2 | |
| SCHEMBL559277 | 0.71 | MAPK8 (0.46) | PDE10AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | CHEK2 120/4885PDE3B 4349/4885PDE3A 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.